| VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA a Milos TABORSKY. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2013, roč. 157, č. 1, s. 50-55. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2012.078. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1170060,
author = {Vaclavik, Jan and Sedlak, Richard and Jarkovský, Jiří and Kocianova, Eva and Taborsky, Milos},
article_location = {Olomouc},
article_number = {1},
doi = {http://dx.doi.org/10.5507/bp.2012.078},
keywords = {resistant hypertension; spironolactone; clinical trials; blood pressure; secondary hypertension},
language = {eng},
issn = {1213-8118},
journal = {Biomedical Papers, Olomouc: Palacky University},
title = {The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension},
volume = {157},
year = {2013}
}
TY - JOUR
ID - 1170060
AU - Vaclavik, Jan - Sedlak, Richard - Jarkovský, Jiří - Kocianova, Eva - Taborsky, Milos
PY - 2013
TI - The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension
JF - Biomedical Papers, Olomouc: Palacky University
VL - 157
IS - 1
SP - 50-55
EP - 50-55
PB - Palacky University
SN - 12138118
KW - resistant hypertension
KW - spironolactone
KW - clinical trials
KW - blood pressure
KW - secondary hypertension
N2 - Aims. There are currently limited data about whether the effect of spironolactone in patients with resistant arterial hypertension depends on baseline blood pressure and the presence of a secondary cause of hypertension. Methods. Patients with office systolic blood pressure (BP) > 140 mmHg or diastolic BP > 90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Results. Analyses were done with 55 patients treated with spironolactone. The degree of BP reduction after 8 weeks of spironolactone treatment did not differ significantly between the three tertiles of baseline systolic BP and patients with and without a secondary cause of hypertension. The reduction of office systolic, office diastolic BP and office pulse pressure was significantly lower in the highest tertile with baseline diastolic BP > 97 mmHg. Conclusions. Spironolactone treatment is effective to a similar extent both in patients with and without a secondary cause of hypertension and regardless of the baseline value of systolic BP. Less effect of spironolactone was found in patients with the highest baseline diastolic BP.
ER -
VACLAVIK, Jan, Richard SEDLAK, Jiří JARKOVSKÝ, Eva KOCIANOVA a Milos TABORSKY. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2013, roč.~157, č.~1, s.~50-55. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2012.078.
|
